Upgrade to SI Premium - Free Trial

Stifel on Biogen (BIIB): Apellis acquisition 'surprising,' but makes sense given move towards rare kidney

March 31, 2026 9:42 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $214.00 price target on Biogen (NASDAQ: BIIB)The analyst commented, "Biogen's acquisition ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments